← Back to headlines
Recursion Outlines Financial Runway into Early 2028
Recursion Pharmaceuticals has provided an update on its financial outlook, projecting a runway into early 2028 while aiming to keep 2026 cash operating expenses under $390 million.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
